SCHEMBL535259

SCHEMBL535259

C[CH]Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.50
ACHE P22303 2/20 0.50
PTGS2 P35354 2/20 0.50
HSPB1 P04792 1/20 0.50
ALDH1A1 P00352 4/20 0.49
CYP3A4 P08684 2/20 0.49
MAPK1 P28482 2/20 0.49
GAA P10253 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
THRB P10828 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA9 Q16790 1/20 0.48
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
APP P05067 2/20 0.48
BCL9 O00512 1/20 0.46
CTNNB1 P35222 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11878229 0.84 PTGS2 (0.47) HSD17B10ACHEPTGS2HSPB1ALDH1A1
SCHEMBL8433 0.81 HSPB1 (0.52) HSD17B10ACHEPTGS2HSPB1ALDH1A1
SCHEMBL28135398 0.79 HSPB1 (0.50) HSD17B10ACHEPTGS2HSPB1ALDH1A1
SCHEMBL28049499 0.79 HSPB1 (0.50) HSD17B10ACHEPTGS2HSPB1ALDH1A1
SCHEMBL28049513 0.79 HSPB1 (0.50) HSD17B10ACHEPTGS2HSPB1ALDH1A1
SCHEMBL13665383 0.79 HSPB1 (0.55) HSD17B10ACHEPTGS2HSPB1ALDH1A1
SCHEMBL5847950 0.79 HSPB1 (0.50) HSD17B10ACHEPTGS2HSPB1ALDH1A1
Ammonia Solution, Strong SCHEMBL27663814 0.79 HSPB1 (0.50) HSD17B10ACHEPTGS2HSPB1ALDH1A1
Hydrochloric Acid SCHEMBL27912110 0.79 HSPB1 (0.50) HSD17B10ACHEPTGS2HSPB1ALDH1A1
SCHEMBL830158 0.79 HSPB1 (0.50) HSD17B10ACHEPTGS2HSPB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247431-B2 Heterocyclic hydrazide compound and pesticidal use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-21 US disclosed
EP-2144898-B1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL CO (JP) 2012-02-08 EP disclosed
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed
CN-1478077-A Benzamide compounds as APO B secretion inhibitors ����ҩƷ��ҵ��ʽ���� 2004-02-25 CN disclosed
US-6166023-A 1,5- and 3-O-substituted 1H-indazoles having anti-asthmatic, anti-allergic, anti-inflammatory, immunomodulating and neuroprotective action, process for their preparation and their use as medicaments ARZNEIMITTELWERK DRESDEN GMBH (DE) 2000-12-26 US disclosed
US-5719171-A INSECTICIDES; MITICIDES; NEMATOCIDES; FUNGICIDES BASF AKTIENGESELLSCHAFT (DE) 1998-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME ACHE, CAT, DNPH1 HSD17B10 723/4885ACHE 1/4885PTGS2 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.